Lexeo’s LX2020 Earns RMAT Designation for PKP2 Cardiomyopathy Treatment — Lexeo Therapeutics, Inc.

Event summary

Lexeo Therapeutics' LX2020 gene therapy for PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM) received FDA RMAT designation on August 5, 2026.
The designation follows interim data from the ongoing HEROIC-PKP2 Phase I/II trial.
LX2020 now holds RMAT, Orphan Drug, and Fast Track designations from the FDA.
PKP2-ACM affects approximately 60,000 people in the U.S., with no approved disease-modifying treatments currently available.

The big picture

Lexeo’s RMAT designation for LX2020 underscores the growing momentum in gene therapy for rare cardiovascular diseases. The FDA’s expedited programs are increasingly shaping the development path for genetic medicines targeting high-unmet needs, particularly in conditions like PKP2-ACM where no disease-modifying therapies exist. Lexeo’s ability to leverage these designations could set a precedent for other gene therapy candidates in similar spaces.

What we're watching

Regulatory Acceleration: How RMAT designation will expedite LX2020’s development and review process, potentially leading to accelerated approval.
Clinical Data Impact: Whether interim data from the HEROIC-PKP2 trial will continue to support LX2020’s efficacy and safety profile.
Market Opportunity: The pace at which Lexeo can capitalize on the unmet need in PKP2-ACM, given the lack of approved treatments.